SpineGuard: Stock Trading Will Resume on March 31, 2020

PARIS & BOULDER, Colo.--()--Regulatory News:

SpineGuard (Paris:ALSGD) (FR0011464452 – ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, announced today the stock trading will resume.

Further to the Company's last press release dated March 24, 2020 on the evolution and perspectives of the safeguard proceedings, the Company announces that the stock trading on Euronext Growth (Ticker: ALGSD and ISIN: FR0011464452), that was halted since February 13, 2020, will resume on March 31, 2020.

Pierre Jérôme, co-founder, Chairman and CEO of SpineGuard, said: “We are already working on the elaboration of a safeguard plan and are confident that it will enable the amendment of our debt. In parallel, we are pursuing the deployment of our DSG technology and the set-up of strategic partnerships on a sound basis while taking the necessary measures to cope with the propagation of the COVID-19 virus and its consequences on our activities.”

About SpineGuard®
Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 75,000 surgical procedures worldwide. Fifteen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these solid fundamentals and several strategic partnerships, SpineGuard has expanded its technology platform in a disruptive innovation: the « smart » pedicle screw launched late 2017 and is broadening the scope of applications in dental implantology and surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer.

For further information, visit www.spineguard.com

Disclaimer
The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

Contacts

SpineGuard
Pierre Jérôme

Chairman and CEO
Tél. : +33 1 45 18 45 19
p.jerome@spineguard.com

Manuel Lanfossi
Chief Financial Officer
m.lanfossi@spineguard.com

Europe / NewCap
Investor Relations & Financial Communication
Mathilde Bohin / Pierre Laurent
Tél. : +33 1 44 71 94 94
spineguard@newcap.eu

Contacts

SpineGuard
Pierre Jérôme

Chairman and CEO
Tél. : +33 1 45 18 45 19
p.jerome@spineguard.com

Manuel Lanfossi
Chief Financial Officer
m.lanfossi@spineguard.com

Europe / NewCap
Investor Relations & Financial Communication
Mathilde Bohin / Pierre Laurent
Tél. : +33 1 44 71 94 94
spineguard@newcap.eu